leisure time -WSS

leisure time

author：leisure time 2025-10-01 01:50:53 - browse：6653

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： 2 officers injured in shooting in Orlando, police say

WSS

Anthony Fauci pushes back on GOP claims during Covid hearing

How CO2 helps viruses stay alive longer in the air

Medicare Advantage's lean provider networks lead CMS complaints

2 officers injured in shooting in Orlando, police say

CMS got Medicare Advantage quality rating wrong, judge rules

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Wikipedia

leisure time

entertainment

How one medical school became remarkably diverse

Florida officials tell state schools to teach AP Psychology 'in its entirety'

United colonoscopy coverage change 'may cost lives,' doctors say

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Duchenne breakthrough therapy leaves behind pioneering families

Heart disease in astronauts blamed on cosmic radiation

23andMe had bad news about my health. I wish a person had delivered it

Medicare Advantage's lean provider networks lead CMS complaints

Walensky prepares to leave CDC — and Congress — behind

FDA approves Moderna’s RSV vaccine, its second licensed product

leisure time

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Elevance PBM president out as customers face prescription chaos

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Pharma showers House GOP doctor with campaign cash

FTC loses bid to block Novant's North Carolina hospital merger

CMS got Medicare Advantage quality rating wrong, judge rules

focus

explore

explore

Wikipedia